Abstract 17P
Background
Emerging evidence shows that exosomal miRNAs (Exo-miRNAs) mediate crosstalk between breast cancer (BC) cells and the tumor microenvironment (TME), modulating cancer hallmarks. FDG-PET/CT is increasingly used for restaging and detecting distant metastasis in BC patients, but its high cost and radiation hazard limit its use, especially in resource-limited settings. Owing to their stability and functional activity, Exo-miRNAs are being explored as non-invasive alternative biomarkers in several cancers. This study aims to develop an Exo-miRNA panel as a complementary tool for predicting metastasis and staging BC patients.
Methods
We enrolled 78 BC patients referred for FDG-PET/CT between 03/2022 and 10/2023. FDG-PET/CT was used as the reference standard for staging and metastasis. Exo-miRNAs were profiled from plasma using next-generation sequencing. In the discovery phase, 18 patients were randomly selected and categorized into three groups: Early (stage I+II, n=6), Advanced localized (stage III, n=6), and Metastasis (stage IV, n=6). Differentially expressed Exo-miRNAs (DE-Exo-miRNAs) were identified using DESeq2 with a fold change cutoff of <1.5> and an adjusted p-value < 0.05 followed by qPCR validation.
Results
We identified 22 DE-Exo-miRNAs across the groups, including unique and common miRNAs. For Early vs. Advanced, hsa-miR-122-5p and hsa-miR-183-5p were upregulated, while hsa-miR-203a-3p was downregulated. In Early vs. Metastatic, hsa-miR-92a-2-3p and hsa-miR-320a-3p were upregulated, whereas hsa-let-7a-5p and hsa-miR-486-5p were downregulated. hsa-miR-22-3p, hsa-miR-23b-3p, and hsa-miR-146a-5p were uniquely upregulated, highlighting their potential for differentiating stage IV patients from I & II. For Advanced vs. Metastatic, hsa-miR-92a-2-3p, hsa-miR-320a-3p, and hsa-miR-100-5p continued upregulation, while hsa-miR-26b-5p, hsa-miR-7-5p, and hsa-miR-222-3p were downregulated in metastatic patients. Gene ontology and pathway analysis supported DE-Exo-miRNAs as important regulators of disease pathology.
Conclusions
Our findings highlight the potential of Exo-miRNAs as biomarkers for predicting progression and metastasis risk with advantages of lower cost and broader accessibility.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
D.A. Khan.
Funding
Higher Education Commission (HEC) Pakistan (Grant ID# 20-16564).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Development of a cell-free DNA scoring system from organoid culture medium to predict drug response in bladder cancer
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Quinacrine inhibits angiogenesis and migration of non-small cells lung cancer cells (NSCLC) by binding with the kinase domain of VEGFR2
Presenter: Angshuman Sarkar
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - HDAC6-mediated regulation of progesterone receptor: Implications for hormonal therapy in breast cancer
Presenter: Wafaa Ramadan
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Functional impact of miR-205-5p on cervical cancer cell behavior and chemotherapy response
Presenter: Rhafaela Causin
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Impact of poly(ADP-ribose) polymerase (PARP) mutations on interaction with PARP inhibitors (iPARPs)
Presenter: JUAN DIAZ ACOSTA
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma in multicellular spheroid model
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Clinical phenotyping of lung cancer-associated cachexia in relation to tumour volume in TRACERx
Presenter: Kexin Koh
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Are patients with measurable residual disease (MRD) positive or MRD negative different in baseline DNA methylation signatures in precursor B-cell acute lymphoblastic leukaemia (B-ALL)?
Presenter: Ramya Ramesh
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Prognostic value of tumor location and site-specific metastases in advanced biliary tract cancer
Presenter: Vanessa Patel
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes
Presenter: Rowan Howell
Session: Cocktail & Poster Display session
Resources:
Abstract